

Aurealis Pharma Extends Microbiology, Genetic Engineering and Manufacturing Expertise by Recruitment of Industry Expert Dr. Igor Mierau

Basel Switzerland, Kuopio Finland – January 22nd 2016.

Aurealis Pharma, a privately owned biopharmaceutical company focused on developing innovative treatment options for patients with chronic inflammation and cancer, announced today the appointment of Dr. Igor Mierau, PhD, as a Director of Microbiology, Genetic Engineering and Fermentation.

Dr. Mierau has 30 years of experience in working with lactic acid bacteria and their use in gene expression. He has MSc in microbiology and microbial genetics from the Friedrich-Schiller-University Jena, Germany, and PhD in molecular genetics of lactic acid bacteria from the University of Groningen, The Netherlands. After his extensive academic career he was first a Senior Researcher at Snow Brand European Research Laboratories BV Groningen and for 15 years a Project Manager and Biological Safety Officer at NIZO food research, Ede, Netherlands.

“Igor’s remarkable expertise in genetic engineering and manufacturing of lactic acid bacteria as well as his understanding on their use as a bioreactor to produce therapeutic proteins is a tremendous value asset for the company. We are more than pleased to have him onboard as we advance towards clinical trials in diabetic foot ulcer and cancer” said Aurealis Pharma CSO Thomas Wirth.

“I am very familiar with the enormous potential of genetically engineered lactic acid bacteria based products for decades, and thus I am excited to be part of the Aurealis Pharma team and contributing to the development of these bacteria for the benefit of cancer and chronic wound patients” states Dr. Mierau.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

For more information:

Juha Yrjänheikki, CEO, Aurealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)



AUREALIS PHARMA

Microkatu 1 Greifengasse 11
FI-70210 Kuopio CH-4058 Basel
Finland Switzerland
www.aurealispharma.com